HU204428B - Celaning composition for prothesis - Google Patents

Abstract

A denture cleaning prepn. contains samarium cpds. pref. samarium-sulpho -salicylic-acid complex and methylene-blue as anti-inflammatory and disinfecting agents. It also contains sulphanylic acid and alkali nitrites to prevent deposition of dangerous amine cpds. To control oxygen evolution a metal complex with a suitable dissociation constant is used, namely a chromium or manganese complex of EDTA or nitrilo-tri:acetic acid or of di:amino-cyclo-hexyl-tetra:acetic-acid. The prepn. also contains appropriate quantities of boric acid stabilised sodium-perborate-hydrate as a source of oxygen; sodium-dodecyl- as surfactant, an alkali hydrogen-carbonate to liberate carbon dioxide and a complexing agent

Description

BACKGROUND OF THE INVENTION The present invention relates to a two- or three-phase denture cleanser containing a surfactant, a complexing agent, an oxidizing agent, a carbon dioxide generating agent, an anti-inflammatory and bactericidal agent, a catalyst, and an antimicrobial agent, and an antiinflammatory and bactericidal agent. (ΠΙ) - anhydride or samarium - (EH) - sulfosalicic acid complex or samarium - (ΠΙ) chloride or samarium compound and methylene blue, ethylene diamine as a catalyst, or - manganese salt, or nitrilotriacetic acid, or - chromium salt, or diaminocyclohexyltetraacetic acid, chromium manganese, or - disodium salt, or nitrilotriacetic acid, or diaminocydohexyl tetraacetic acid, and alkaline for the decomposition of amino compounds. contains nitrite.

A variety of dentifrice compositions of various compositions are known in the art. The most important detergents used in this detergent are various active oxygen compounds or mixtures thereof, such as sodium perborate monohydrate, sodium perborate tetrahydrate, potassium persulfate, or sodium percarbonate.

When dissolved in water, these materials release active oxygen and form bubbles which purify the denture from the tartar by oxidation and restore its original color.

Often, dichloroisocyanic acid, or its alkali salt or sodium chloride, is used as an additive in the presence of hyperthermic acid in the presence of these compounds.

The disintegration of tablet-form cleaners and thus their rapid and complete dissolution and cleaning effect can also be enhanced by the development of carbon dioxide bubbles.

Tablets exhibiting carbon dioxide evolution are compositions of carbonic acid salts such as sodium bicarbonate, sodium carbonate, potassium bicarbonate, or potassium carbonate and citric acid, tartaric acid, or phosphoric acid derivatives.

When the tablet is placed in water, the components react with each other during the evolution of 40 carbon dioxide. This facilitates the cleaning effect and disintegration and complete dissolution of the tablet by mechanical agitation.

The tablets may also contain antiseptics, fillers, binders and lubricants, indicators, colorants and flavors.

Often, ionic or nonionic steroids are also added to enhance the cleaning effect. These surfactants contain a hydrophilic and a lipophilic group. The ionic surfactants may be anionosokpl. soaps, females, alkane sulfonates, olefin sulfonates, alkylarylsulfonates, pLdodexylbenzene sulfonates, and the like.

Cationic surfactants include benzalkonium chlorides, quaternary ammonium salts, amine salts, and the like. Nonionic surfactants include alkyl phenol polyglycol ethers, ethoxylated products of fatty acids and fatty acid amides, and the like.

The use of sodium perborate as an oxidizing agent is described in the following patents:

U.S. Pat. No. 3,372,125 60

U.S. Patent 3,488,288, U.S. Patent 3,821,117, U.S. Patent 4,066,566, U.S. Patent 4,115,293, U.S. Patent No. 4,362,639, German Patent 2,437,491, U.S. Patent 2,548,869, U.S. Patent No. 1,527,010, U.S. Patent No. 2,095,694. other substances than those recommended by us for controlling oxygen release.

German Patent No. 2,357,720 to Kukirol-Fabrik protects a multiphase denture cleaning tablet and its preparation. The rapidly dissolving phase of the patented tablet softens the water used as a solvent and binds its metal components. As a result, the loading area on the denture increases, absorbing and reducing effects on the staining and odor materials. Then, the second phase dissolves, which oxidizes the materials formed during the first plating and prevents the build-up.

Thus, in the case of multiphase tablets, the disadvantage of the single phase tablets is that the simultaneous action of the oxidizing and reducing chemical agents therein, weakens one another, and the particle disintegration and water softening are too late, and thus too late.

The composition of the denture cleaning tablet disclosed in German Patent A2,357.720 is as follows:

The composition of the first phase:

35-501% sodium bicarbonate

20-301% sodium hexametaphosphate

2-201% citric acid

2-61% ethylenediaminetetetracetate salt

1-41% high molecular weight polyethylene glycol

0-21% of improved bentonite

0-11% glyceride derivative

0.5 to 21% blowing agent

0-21% hydroxybenzoic acid

0.5-1.51% peppermint oil or powder

Second phase composition:

15-251% sodium bicarbonate

8-151% sodium hexametaphosphate

10-201% sodium citrate

10-151% sodium pyrophosphate

25-351% Caroic acid salt

1-41% polyethylene glycol

0-41% foaming agent

1-21% Tamol and Dye

3- 61% soluble starch

0-21% fatty acid sugar ester salt

0-21% hydroxybenzoic acid salt

0-3 t% Boeson

0.5-1.51% peppermint oil or powder

The multiphase denture cleansing tablet and its preparation are also described in German Patent 2,647,364.

HU 204428 Β

The composition of the denture cleaning tablet described in the above patent is characterized by the following data:

The composition of the first phase:

35-50% by weight sodium bicarbonate

20-301% Sodium Hexametaphosphate

15-201% sulfamic acid

2-61% ethylenediaminetetraacetate

1-41% high molecular weight polyethylene glycol

0.1 to 21% sodium xylene sulfonate

0-21% bentonites

0-11% triglyceride derivative

0.5-21% surfactant

1-31% polyvinylpyrrolidone

0-2% by weight of 4-hydroxybenzoic acid alkyl ester or other disinfectant

0.5-1.51% peppermint powder

The composition of the second phase:

15-251% sodium bicarbonate

8-151% sodium hexametaphosphate

1-81% ethylenediaminetetraacetate

10-151% sodium hydrogen pyrophosphate

25-351% Caroic acid salt -41% high molecular weight polyethylene glycol

0.1-21% polyvinylpolypyrrolidone

1-3% by weight of calcium hydrogen phosphate

3- 61% soluble starch

0-21% fatty acid sugar ester

0-2% by weight of alkyl ester of 4-hydroxybenzoic acid or other disinfectant

0-31% trifliceride derivative

0.5-1.51% peppermint powder

0.1-1% by weight of silica

Surprisingly, it has now been found that a cleaning agent with better properties than the known denture cleaners can be prepared by providing antiinflammatory and bactericidal agents such as: samarium (III) anhydride or samarium (m) chloride or samarium (DI) sulfosalicylic acid. a complex or the aforementioned samarium compound and methylene blue; in addition, the decomposition of amino compounds on dentures and alkaline nitrite; and, for the regulation of oxygen evolution, ethylene-diaminotheta-acetic acid chromium or manganese complex or nitrilotriacetic acid-chromium or sodium complex or diamino-cyclohexyl-tetraacetic acid chromium or sodium or manganese complex, or

It also contains a suitable amount of an oxidizing agent, a surfactant, a carbon dioxide generating agent, and a suitable amount of an alkali-ethylenediaminetetraacetic acid salt as a complexing agent.

The oxidizing agent may be, for example, sodium perborate monohydrate or sodium perborate tetrahydrate or potassium persulfate or sodium percarbonate, or a mixture thereof, or a mixture containing an alkaline salt of dichloroisocyanic acid and an alkali chloride to form hypochlorite.

These active oxide-containing compounds oxidize the constituents of tartar and restore denture strength.

Ionic or nonionic products containing hydrophilic and lipophilic groups, or mixtures thereof, for example as a tenside-cleaning process, can be used to reduce labor requirements. ethoxylated derivatives of alkanesulfonates, alkylarylsulfonates, alkylphenol polyglycol ethers, fatty acids and fatty acid amides quaternary ammonium salts

As the carbon dioxide generating component which enhances the disintegration and rapid and complete dissolution of the tablet, for example, an alkali hydrogen carbonate or an alkaline carbonate, a cut / blend thereof and citric or tartaric acid or a phosphoric acid derivative or a mixture thereof.

The detergent also contains complexing agents for dissolving the dental metal compounds in solution. Suitable complex or chelating agents for this purpose are, for example, alkali metal salts of ethylenediaminetetraacetic acid, alkaline salts of nitrileoacetic acid, diethylenetriaminepentaacetic acid, N- ( 2-hydroxy-ethyl) ethylenediamine triecetsavas-alkali salts.

It is known that the use of dentures can lead to gingivitis, partly due to a lack of fit in the denture and partly to individual hypersensitivity. It was intended to utilize the known anti-inflammatory properties of the samarium (m) compounds, supplemented by the discovery of using a samarium compound having the corresponding hydrolytic properties, for example, the samarium (III) sulfosalicylic acid complex or the samarium (III) anhydride. or samarium (in) chloride. During cleaning, they visibly adhere to the surface of the denture and thus exhibit an anti-inflammatory effect at the interface between the gum and the denture when used. In many respects, the use of methylene blue, which together with the samarium compound activated by hydrolysis, has bactericidal activity and is therefore advantageous for oral hygiene, is preferred.

We have discovered that methylene blue also acts as an indicator in the composition of the composition we propose. The disappearance of the oxidizing effect is accompanied by a sharp change in color and the color of the solution changes from blue to green, thus automatically indicating to the user the completion of the cleaning operation.

The use of alkaline nitrite has led to the discovery that this compound degrades the health-damaging amino compounds in the denture from the environment of food decomposition and the environment. In the acidic medium formed by the rapid dissolution of sulfamic acid, the aromatic amines are diazotized in the presence of the nitrite ion liberated from the alkali nitrile and thus dissolved. The aliphatic primary amines are deaminated. Thus, nitrosamines which are harmful to health cannot be formed.

According to our experiments, ethylene-diaminotetraacetic acid or nitrilotriacetic acid, or cyclohexyltetraacetic acid-chromium and manganese complexes are more suitable than previously known for controlling catalytic oxygen liberation. The catalytic activity can be varied within wide limits.

The following examples illustrate the denture cleansing tablets and their preparation according to the invention.

HU 204428 Β

These examples are provided for illustrative purposes only, without limiting the invention thereto.

Example I

Three-Phase Dental Mix & I tablet Composition 5 and Preparation Phase A:

6.901% dodecyl sulfate sodium salt

II, 501% sodium bicarbonate

2.30% by weight of ethylenediaminetetraacetic acid disodium salt

3.50% by weight of ethylenediaminetetraacetic acid chromium (ni) salt

0.231% samarium (III) anhydride 0.11t% diluted methylene blue 15

0.0111% methylene blue

0.0641% Potassium Dihydrogen Phosphate 0.040% Sodium Hydrocarbonate 27.501% Sulfamic Acid is thoroughly homogenized by mixing diluted methylene blue with 10.01% methylene blue, 55.61% potassium dihydrogen phosphate and 34.41% sodium bicarbonate.

Phase B:

32.021% sodium perborate hydrate and

13.701% boric acid is thoroughly homogenized

Making pills:

2 g of phase B pastilles are compressed and topped with 0.1 g (2.301%) of sodium nitrite to form phase C and 2.26 g of phase A to form a complete tablet.

Finally, the compressed three-phase tablets are individually airtight.

Example 2

The procedure is the same as in Example 1, except that the samarium sulfosalicylic acid complex is used instead of the samarium (lir) anhydride.

Example 3 ₀

In the same way as in Example l, except that in the preparation of phase A,

6.901% dodecyl sulfate sodium salt

9.20% sodium bicarbonate

4.60% by weight of disodium salt of ethylenediaminetetraacetic acid

3.501% manganese salt of ethylenediaminetetraacetic acid

0.231% samarium (III) anhydride

0.11% by volume of dilute methylene blue

27.501% sulfamic acid is thoroughly homogenized.

Example 4

The procedure is the same as in Example 2, except that in the preparation of phase A

6.901% dodecyl sulfate sodium salt

13.701% sodium bicarbonate

1.15% by weight of disodium salt of ethylenediaminetetraacetic acid

2.30% ethylenediaminetetraacetic acid chromium salt ¹

0.461% samarium sulfosalicylic acid complex

0.11t% dilution methylene blue

27.301% sulfamic acid is homogenized

Example 5

The procedure is the same as in Example 2, except that in the preparation of Phase A

8.901% dodecyl sulfate sodium salt

11.501% sodium bicarbonate

4.601% ethylenediaminetetraacetic acid disodium

3.501% chromium salt of ethylenediaminetetraacetic acid

0.461% samarium sulfosalicylic acid complex

0.111% diluted methylene blue and

22.91% sulfamic acid is homogenized

Example 6

The procedure of Example 2 is followed except that the nitrile tri triacetic acid chromium salt is used in place of the ethylene 20 -diamino-tetraacetic acid chromium salt.

Example 7

In the same manner as in Example 2, only the nitrilotriacetic acid manganese salt is used instead of the ethylenediaminetetraacetic acid chromium salt and the nitrilotriacetic acid sodium salt is used instead of the ethylene dianunoetetraacetic acid disodium.

Example 8

The procedure is the same as in Example 2, except that the diammocyclohexyltetraacetic acid chromium salt is substituted for the ethylenediaminetetraacetic acid chromium salt, and the pe35 dig digiaminocyclohexyltetraacetic acid disodium is used instead of the ethylenediaminetetraacetic acid disodium.

Example 9

The procedure of Example 2 is followed except that diaminocyclohexyl tetraacetic acid manganese salt is used instead of ethylenediaminetetraacetic acid chromium salt and diaminocyclohexyltetraacetic acid disodium is used instead of ethylenediaminetetraacetic acid disodium.

Example 10

The procedure is the same as in Example 2, except that in the preparation of phase A

2.301% dodecyl sulfate sodium salt

11.501% sodium bicarbonate

2.301% ethylenediaminetetraacetic acid disodium

3.501% chromium salt of ethylenediaminetetraacetic acid

0.231% samarium sulfosalicylic acid complex

32.101% sulfamic acid was used

Example 11

The procedure is the same as in Example 1, except that, A '. > Extrude pastilles from an appropriate amount of phases B, B and C, and the pastilles

HU 204428 Β mechanical pressure to combine into a pastille.

Example 12

The phase

11.501% sodium bicarbonate

2.301% sodium nitrite

6.901% dodecyl sulfate sodium

3.501% chromium salt of ethylenediaminetetraacetic acid

0.231% samarium sulfosalicylic acid complex

0.11t% diluted methylene blue

2.30% by weight of ethylenediaminetetraacetic acid disodium is homogenized.

Weigh 1 g of the above homogenate into an airtight bag and measure 1.2 g (27.501%) of sulfamic minic acid to seal the bag.

Phase "B" was prepared as described in each example and weighed 2 to 2 g in a sachet. When used, place the denture to be cleaned in 200 ml of water at 40-60 ° C, then add the composition in the Stage A pouch, and after a few minutes add the composition in the Stage B pouch.

Example 13

The procedure is the same as in Example 1, except that when preparing the A phase

6.901% dodecyl sulfate sodium salt 11.501% sodium bicarbonate 2.30% ethylenediaminetetraacetic acid disodium salt

3.501% chromium salt of ethylenediaminetetraacetic acid 0.231% samarium (III) anhydride 0.111% diluted methylene blue 27.501% sulfamic acid

0.23% by weight of ethylenediaminetetraacetic acid is homogenized

Example 14

The procedure is the same as in Example 1, with the exception of awata, in the preparation of phase A

6.90t% dodecyl sulfate sodium salt 11,501% sodium bicarbonate

2.301% Ethylenediaminetetraacetic acid disodium

3.501% chromium salt of ethylenediaminetetraacetic acid

0.23% by weight of samarium (III) anhydride

0.111% diluted methylene blue 10 27.50% sulfamic acid

0.23% by weight of nitrilotriacetic acid is homogenized.

Claims (1)

A two- or three-phase denture cleanser containing a surfactant, a complexing agent, an oxidizing agent, a carbon dioxide generating agent, an anti-inflammatory and bactericidal agent, a catalyst, and components for destroying amino compounds in addition to the additives commonly used in such formulations. as an anti-inflammatory and bactericidal agent, 0.01 to 21% of samarium (III) anhydride or a compound of samarium and 0.01 to 1% of methylene blue based on the total weight of the composition, 0.1 to 5% by weight of ethyl chromium or manganese salt as ethylene , or nitrilotriacetic acid sodium or chromium salt, or diaminocyclohexyl tetraacetic acid chromium, manganese, or disodium salt, or ethylenediaminetetraacetic acid, or nitrilotriacetic acid, or diaminocyclohexyl tetraacetic acid, and amine compounds KOMPO 1-51% alkaline nitrite and 25-351% sulfamic acid 35 included.